Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia

Sarkar, Chandrani; Chakroborty, Debanjan; Dasgupta, Partha; Basu, Sujit

doi:10.1002/ijc.29414

Cited by 40 publications

(47 citation statements)

References 24 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The anti-Parkinsonian drug dopamine was recently reported to inhibit vascular endothelial growth factor A (VEGFA) and tumor angiogenesis (50), thus possibly lowering cancer risk. In the current study only a small number of patients were treated solely with dopamine, however patients that were treated with dopamine agonists or other medical combinations that contain dopamine did not have statistically significant lower CRC risk.…”

Section: Discussionmentioning

confidence: 99%

Parkinson’s disease and colorectal cancer risk—A nested case control study

Boursi

Mamtani

Haynes

et al. 2016

Cancer Epidemiology

View full text Add to dashboard Cite

Background A pro-inflammatory gut microbiota was described in both Parkinson’s disease and colorectal cancer (CRC) and recently α-synuclein was demonstrated in the enteric nervous system. We sought to evaluate the association between Parkinson’s disease and CRC. Methods We conducted a nested case-control study using a large primary-care database. Cases were defined as all individuals with CRC. Up to 4 controls were matched with each case based on age, sex, practice-site and duration of follow-up. The primary exposure of interest was diagnosis of Parkinson’s disease prior to CRC as well as disease duration, and Parkinson’s specific therapies. The primary analysis was a conditional logistic-regression to estimate odds ratios (ORs) and 95% confidence interval (95%CI). Results The study included 22,093 CRC cases and 85,833 matched controls. Past medical history of Parkinson’s disease >1 year before index-date was associated with lower CRC risk (OR 0.74, 95%CI 0.59–0.94). The inverse association was more prominent among females compared to males (0.64, 95%CI 0.42–0.96 and 0.8, 95%CI 0.60–1.07, respectively). While patients who received no therapy or therapy with dopamine agonists had a non-significant decrease in cancer risk, patients who were treated with dopamine had a non-significant elevated cancer risk. Conclusion Parkinson’s disease is inversely associated with CRC risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Parkinson’s disease and colorectal cancer risk—A nested case control study

Boursi

Mamtani

Haynes

et al. 2016

Cancer Epidemiology

View full text Add to dashboard Cite

show abstract

“…Dopamine receptors (DRD1-5) mainly reside in the human brain, which play important roles in cancer tumorigenesis and progression [5][6][7][8][9]. DRD2 agonists inhibit the growth of lung cancer cells including NSCLC and small cell lung cancer [6,10,11].…”

Section: Introductionmentioning

confidence: 99%

Overexpressed D2 Dopamine Receptor Inhibits Non-Small Cell Lung Cancer Progression through Inhibiting NF-κB Signaling Pathway

Zhang

Deng

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Non-small cell lung cancer (NSCLC) is one of the deadliest cancers worldwide. Dopamine receptor D2 (DRD2) has multiple roles in clinical progression of NSCLC and functional maintenance of cancer cells. However, little is known about the molecular mechanism. Here, we clarified whether DRD2 inhibits lung cancer progression and identified the underlying downstream signaling. Methods: DRD2 mRNA and protein levels were detected in clinical specimens by qRT-PCR and immunohistochemistry, respectively. MTT and colony formation assays were applied to analyze cell proliferation. The underlying molecular mechanism was identified by dual luciferase, western blot, qRT-PCR, cAMP detection, immunoprecipitation, and chromatin immunoprecipitation assays. A murine NSCLC model was used to clarify the role of DRD2 in tumor cell proliferation. Results: We found that DRD2 ablated tumor cell growth. DRD2 expression in NSCLC tissues was lower than in adjacent normal lung tissues. Moreover, DRD2 mRNA and protein levels in NSCLC were negatively correlated with the tumor size, TNM status, and patient overall survival. In vitro experiments showed that disruption of DRD2 promoted the proliferation of NSCLC cell lines A549 and SK-MES-1 by inhibiting the NF-κB signaling pathway. Furthermore, DRD2 overexpression not only blocked lipopolysaccharide-induced A549 and SK-MES-1 cell proliferation and growth, but also inhibited the tumorigenesis in murine xenograft models. Conclusion: These results indicate that DRD2 may be a potential therapeutic target for lung cancer patients with high DRD2 expression by ablating the NF-κB signaling pathway.

show abstract

“…Second, the treatment of PD may provide another explanation. Dopamine, which is a drug used in the therapy for PD, was reported to be an effective anti-angiogenic drug for the treatment of malignant tumors [23], thus it may decease the risk of lung cancer. Indeed, our result indicated that the significant inverse relationship between PD and risk of lung cancer could be found in after PD group, but could not be found in before PD group.…”

Section: Discussionmentioning

confidence: 99%

Risk of lung cancer in Parkinson's disease

Xie

Luo

Xie³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Recently, growing evidence has revealed the significant association between Parkinson's disease (PD) and cancer. However, controversy still exists concerning the association between PD and lung cancer. A comprehensive article search for relevant studies published was performed using the following online databases: PubMed, Web of Science and Embase up to August 31, 2016. The pooled risk ratio (RR) and their 95 % confidence intervals (CI) were calculated using the method of inverse variance with the random-effects model. Fifteen studies comprising 348,780 PD patients were included in this study. The pooled result indicated that patients with PD were significantly associated with a decreased risk of lung cancer (RR: 0.53, 95% CI: 0.41−0.70, P < 0.001). In addition, subgroup analyses performed in Western population also confirmed the significant inverse relationship between PD and risk of lung cancer (RR: 0.48, 95% CI: 0.39−0.60, P < 0.001). In the subgroup analysis, a reduced risk of lung cancer in PD patients from Western population was consistent regardless of study design, gender, or study quality. In conclusion, PD patients were significantly associated with a reduced risk of lung cancer in Western population. The relationship between them in Asian population needs to be confirmed by future studies.

show abstract

Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia

Cited by 40 publications

References 24 publications

Parkinson’s disease and colorectal cancer risk—A nested case control study

Parkinson’s disease and colorectal cancer risk—A nested case control study

Overexpressed D2 Dopamine Receptor Inhibits Non-Small Cell Lung Cancer Progression through Inhibiting NF-κB Signaling Pathway

Risk of lung cancer in Parkinson's disease

Contact Info

Product

Resources

About